The TRUdPCR® BCR::ABL1 Major dPCR Kit is an advanced digital PCR assay developed for the absolute quantification of BCR::ABL1 major fusion transcripts (e14a2 and e13a2; P210). Designed for high-performance molecular testing, the kit supports research and laboratory applications involving chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL) sample analysis.
With a streamlined one-step workflow and approximately 90-minute run time, the kit offers a fast and flexible solution for digital PCR-based transcript analysis in laboratory environments.
Key Features of the TRUPCR® BCR::ABL1 Major dPCR Kit
- Powered by ultra-sensitive digital PCR (dPCR) technology for precise BCR::ABL1 transcript quantification without the need for standard curves.
- Uses reaction partitioning and end-point fluorescence detection to deliver highly reproducible results, even in samples with low disease burden.
- Validated across multiple specimen types, including EDTA whole blood, bone marrow, and PAXgene samples.
- Fully compatible with the Applied Biosystems™ Absolute Q Digital PCR System, with seamless software integration for simplified analysis and direct quantification.
- Supplied with validated BCR::ABL1 and ABL1 primer-probe mixes, controls, standards, and RNase-free reagents for reliable assay performance.
- Extensively validated on more than 150 clinical samples, demonstrating robust analytical performance and consistency across a wide range of disease levels.
This product is intended for Research Use Only (RUO) and is not intended for diagnostic or therapeutic decision-making.
For further information download the flyer
To request additional kit details, please complete the form below.
